A, LNCaP-C4–2 cells were preincubated with or without anti-αVβ3, anti-αVβ5 monoclonal antibody, and anti-VEGF/VEGFR-2 and placed in bone extracts from SPARC (+/+) and SPARC (−/−) mice. B, migration of PC3 cells respectively to bone extracts from SPARC (+/+) and SPARC (−/−) mice after treatment with or without anti-αvβ3, anti-αvβ5 monoclonal antibody, and anti-VEGF/VEGFR-2 inhibitors. Cell migration was quantitated by performing microscopic counts of 10–20 random fields at 200X power. The data shown are means ± S.D. of three separate experiments.